Acer Therapeutics (ACER)
(Delayed Data from OTC)
$0.66 USD
0.00 (0.00%)
Updated Nov 20, 2023 03:59 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Acer Therapeutics Inc. [ACER]
Reports for Purchase
Showing records 121 - 140 ( 213 total )
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Healthcare - Yas'' Weekly Recap of Our Key Notes
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Part 3: "Must-See" Companies at JPM (Mkt. Cap. <$100M) With 1Q20 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
ACER-001 Pivotal Trial Part B Enrollment Completion; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
3Q19 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
An Uneventful 3Q19 as Efforts for ACER-001 Continue
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
3Q19 - Pivotal Year Ahead, with All Eyes on ACER-001
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Pivotal ACER-001 Trial Initial Stage Completes Enrollment; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
2Q19 Financial Results Reported; Focus Shifting to Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Biotechnology - Overcoming Challenges in CNS Drug Development
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Healthcare - Earnings Recap: The More Analysis, The Merrier, Especially When Data-Driven
Provider: Roth Capital Partners, Inc.
Analyst: RAHIMI Y
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
HEALTHCARE - 2019 PacGrow Healthcare Conference: Day 2 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Uneventful 2Q19 EPS Report As ACER-001 Prepares to Advance
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Company: Acer Therapeutics Inc.
Industry: Medical - Drugs
Pipeline Update Conference Call Underscores Remaining Promise; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R